How Brain Peptides Like NPY, Oxytocin, and GLP-1 Control Star-Shaped Brain Cells in Neurological and Psychiatric Diseases

What the researchers found

The review identifies nine central neuropeptides that modulate astrocyte state transitions: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), cholecystokinin (CCK), corticotropin-releasing hormone (CRH), angiotensin (Ang), oxytocin (OXT), orexin/hypocretin (OX/HCRT), and glucagon-like peptide-1 (GLP-1). These peptides influence astrocyte proliferation, morphology, and secretory functions, thereby affecting the pathogenesis of both neurodegenerative diseases (Alzheimer's, Parkinson's) and neuropsychiatric disorders (depression, anxiety). Both the neuropeptides and their receptors are positioned as promising therapeutic targets.

Why it matters

Most brain disease research focuses on neurons, but astrocytes play critical roles in brain health and disease that are only now being fully appreciated. Understanding how neuropeptides regulate astrocyte function opens a new therapeutic dimension — rather than targeting neurons directly, treatments could work by using peptides to shift astrocytes into protective modes. This is particularly relevant because several of these peptides (like GLP-1 and oxytocin) already have approved or experimental drug forms.

How the study worked

Narrative review of preclinical research literature examining the effects of nine selected central neuropeptides on astrocyte function and their roles in neurodegenerative and neuropsychiatric disease pathogenesis.

What this study cannot tell us

As a narrative review, the study selection and synthesis methodology is not systematic. The evidence is almost entirely preclinical (cell culture and animal models), with limited human data. The complexity of astrocyte subtypes and regional brain differences may mean that peptide effects vary significantly by brain region and disease context. The review covers nine peptides broadly rather than providing deep mechanistic analysis of each.

How to read the evidence

This is a narrative review summarizing preclinical evidence from cell culture and animal studies. While comprehensive in scope, the underlying evidence is not yet supported by human clinical trials targeting the peptide-astrocyte axis specifically.

When this study was published

Published in 2025, this review captures current understanding of neuropeptide-astrocyte interactions at a time when GLP-1 agonists and other neuropeptides are generating major interest for neurological applications.

The bigger picture

The intersection of neuropeptide research and glial biology is a rapidly growing field. As GLP-1 agonists show unexpected neuroprotective effects in Alzheimer's and Parkinson's trials, and oxytocin is investigated for autism and depression, understanding how these peptides affect astrocytes — not just neurons — becomes critical. This review provides a unified framework for understanding these diverse peptide-astrocyte interactions.

Questions still open

• Which of these nine neuropeptides is closest to clinical translation for astrocyte-targeted therapy in neurological disease?
• Do GLP-1 agonists like semaglutide exert their reported neuroprotective effects primarily through astrocyte modulation?
• Could combination approaches targeting multiple neuropeptide-astrocyte pathways simultaneously be more effective than single-target therapies?

Common questions

Read the original research

Central neuropeptides as key modulators of astrocyte function in neurodegenerative and neuropsychiatric disorders.

Psychopharmacology, 242(11), 2353-2371

Citation

Yang, Meng-Jie; Jia, Min; Cai, Meng; Feng, Xiao; Huang, Li-Ning; Yang, Jian-Jun. (2025). Central neuropeptides as key modulators of astrocyte function in neurodegenerative and neuropsychiatric disorders.. Psychopharmacology, 242(11), 2353-2371. https://doi.org/10.1007/s00213-025-06840-9